{"ticker": {"uuid": "7063861a-0d6e-4680-905a-c88f8f7143ee", "symbol": "BCYC", "name": "Bicycle Therapeutics Ltd", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "ETFs Investing in Bicycle Therapeutics Plc Sponsored ADR Stocks", "summary": "This article lists various ETFs that hold shares of Bicycle Therapeutics Plc Sponsored ADR, providing details such as market value, weight, issuer, expense ratio, and recent performance. The funds are primarily focused on the healthcare and biotechnology sectors, offering investo", "url": "https://www.tradingview.com/symbols/SWB-50BA/etfs/", "source_name": "TradingView", "published_at": "2026-07-14T04:42:40", "published_display": "14 Jul 2026 04:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bicycle Therapeutics (BCYC) CSO executes small RSU tax sell-to-cover trades", "summary": "Bicycle Therapeutics' Chief Scientific Officer, Michael Skynner, conducted two small \"sell-to-cover\" transactions to meet tax withholding obligations on vested Restricted Stock Units (RSUs). These sales, occurring on July 2 and July 6, 2026, involved a total of 2,391 Ordinary Sha", "url": "https://www.stocktitan.net/sec-filings/BCYC/form-4-bicycle-therapeutics-plc-insider-trading-activity-df7ecf8530d6.html", "source_name": "Stock Titan", "published_at": "2026-07-08T12:09:52", "published_display": "08 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BICYCLE THERAPEUTICS (BCYC) CEO executes 7,642-share tax sell-to-cover", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOZnJCbGNDV0NpT2txem4wRUpvYXJyMktrNjZKZy1fdVBVTzZwZFVpZjJ2SWRHMktPbW5QQW9PT0pEZFZaaDdaMDdXS050TTFod3B0U3IzSmxTUDNjMWU3c3phemM3ZkNUbTQxdDRncldMa0hkeUQyRnpNWmdEaWdLUUw1WlRrQ0lsXzdKcnNRTnBkVXItQnJxNGRCNXFtMWh1b1lIeFpTc2l5MEJrMmJZWFlQT0xidDl0OEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T21:00:57+00:00", "published_display": "07 Jul 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics (BCYC) executive sells shares to cover RSU tax withholding", "summary": "Bicycle Therapeutics (BCYC) executive Michael Charles Ferguson sold 1,761 Ordinary Shares across two transactions at weighted average prices of approximately $4.27 and $4.31. These sales were not discretionary but mandated \"sell to cover\" transactions to satisfy statutory tax wit", "url": "https://www.stocktitan.net/sec-filings/BCYC/form-4-bicycle-therapeutics-plc-insider-trading-activity-7ca9bc4981cb.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:35", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics (BCYC) COO sells 1,412 shares in tax-related trades", "summary": "Bicycle Therapeutics COO Jennifer Scott Perry sold 1,412 Ordinary Shares in tax-related transactions on July 2 and July 6, 2026, at prices between $4.27 and $4.34 per share. These sales were mandated \"sell to cover\" for statutory tax withholding obligations from RSU vesting, not ", "url": "https://www.stocktitan.net/sec-filings/BCYC/form-4-bicycle-therapeutics-plc-insider-trading-activity-0479129bb7fd.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:35", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics (BCYC) CFO files sell-to-cover sale of 923 shares", "summary": "Bicycle Therapeutics CFO Travis Alvin Thompson reported a \"sell-to-cover\" sale of 923 Ordinary Shares in two open-market transactions. These sales, totaling $3,945, were executed at weighted average prices of $4.27 and $4.31 to fulfill statutory tax withholding obligations on ves", "url": "https://www.stocktitan.net/sec-filings/BCYC/form-4-bicycle-therapeutics-plc-insider-trading-activity-c34f9f68fd89.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:35", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Bicycle Therapeutics Limited (BCYC)", "summary": "This article analyzes the historical performance of investing $1,000 in Bicycle Therapeutics Limited (BCYC) over various periods, showing significant declines over one and five years. It details the company's focus on developing Bicycle\u00ae molecules for oncology, including drug con", "url": "https://www.stocktitan.net/tools/stock-return-calculator/BCYC", "source_name": "Stock Titan", "published_at": "2026-07-04T23:11:16", "published_display": "04 Jul 2026 23:11", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BCYC (Nasdaq: BCYC) files Rule 144 notice listing RSUs and prior sale", "summary": "Bicycle Therapeutics PLC (BCYC) has filed a Rule 144 notice detailing the proposed sale of common stock and restricted stock units. The filing specifies 12,513 restricted stock units dated July 2, 2026, and 3,594 restricted stock units dated July 3, 2026, alongside a prior sale o", "url": "https://www.stocktitan.net/sec-filings/BCYC/144-bicycle-therapeutics-plc-sec-filing-ff2ed0b717b9.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:02", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Bicycle Therapeutics plc \u2013 NASDAQ:BCYC", "summary": "This article focuses on the \"Price to sales forward\" financial metric for Bicycle Therapeutics plc (NASDAQ: BCYC). It appears to be a stub or a data point from a larger financial analysis platform, providing a snapshot of this specific valuation ratio without further narrative. T", "url": "https://www.tradingview.com/symbols/NASDAQ-BCYC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:39:49", "published_display": "27 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Bicycle Therapeutics plc \u2013 NASDAQ:BCYC", "summary": "The article focuses on the \"Price to earnings forward\" metric for Bicycle Therapeutics plc (NASDAQ: BCYC). It indicates that the market was closed at the time of publication with no trades having occurred. The page provides general financial information and market data for the co", "url": "https://www.tradingview.com/symbols/NASDAQ-BCYC/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:41:12", "published_display": "27 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Bicycle Therapeutics Plc Sponsored ADR \u2013 FWB:50BA", "summary": "This article displays the \"Price to earnings forward\" value for Bicycle Therapeutics Plc Sponsored ADR (FWB:50BA) on the Frankfurt Stock Exchange. It provides a financial overview of the company, indicating the market was closed with no trades at the time of viewing. The content ", "url": "https://www.tradingview.com/symbols/FWB-50BA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:40:26", "published_display": "27 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Bicycle Therapeutics plc \u2013 NASDAQ:BCYC", "summary": "This article provides financial information for Bicycle Therapeutics plc (NASDAQ:BCYC), specifically focusing on its \"Price to book forward\" metric. The content indicates that the market for BCYC was closed at the time of publication, with no trades occurring. The article is part", "url": "https://www.tradingview.com/symbols/NASDAQ-BCYC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T13:40:26", "published_display": "27 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:BCYC)", "summary": "This page provides an overview of Bicycle Therapeutics Plc (NASDAQ:BCYC) financial actuals and analyst estimates. Users can explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average", "url": "https://www.tradingview.com/symbols/NASDAQ-BCYC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T12:39:23", "published_display": "27 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Bicycle Therapeutics Plc Sponsored ADR \u2013 FWB:50BA", "summary": "This article provides financial data for Bicycle Therapeutics Plc Sponsored ADR (FWB:50BA), specifically focusing on its price-to-sales forward ratio. It highlights the company's financial overview on the Frankfurt Stock Exchange via TradingView, indicating that the market was cl", "url": "https://www.tradingview.com/symbols/FWB-50BA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:41:12", "published_display": "27 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "50BA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides the forecast and price target for Bicycle Therapeutics Plc (50BA) trading on the Frankfurt Stock Exchange. It notes a price target of 11.08 based on 9 analysts' 1-year forecasts and mentions that 11 analysts have given stock ratings in the past three months.", "url": "https://www.tradingview.com/symbols/FWB-50BA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:40", "published_display": "26 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics PLC (BCYC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Bicycle Therapeutics PLC (BCYC), noting its current valuation score of 7.85 within the Biotechnology & Medical Research industry. It highlights that the company's P/E ratio is -1.25, while data for P/B, P/S, and P/CF ratios are not ye", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcyc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-25T10:11:44", "published_display": "25 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics shareholders approve all proposals at annual general meeting", "summary": "Bicycle Therapeutics plc announced that all proposals presented at its annual general meeting of shareholders were approved. Shareholders re-elected Felix Baker and Herv\u00e9 Hoppenot as directors, approved executive officer compensation, and ratified the appointments of Pricewaterho", "url": "https://ng.investing.com/news/sec-filings/bicycle-therapeutics-shareholders-approve-all-proposals-at-annual-general-meeting-93CH-2565300", "source_name": "Investing.com Nigeria", "published_at": "2026-06-18T16:10:25", "published_display": "18 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics shareholders approve all proposals at annual general meeting By Investing.com", "summary": "Bicycle Therapeutics plc announced that all proposals at its annual general meeting were approved by shareholders. Resolutions included the re-election of Felix Baker and Herv\u00e9 Hoppenot as directors, advisory approval of executive compensation, and the ratification and re-appoint", "url": "https://za.investing.com/news/sec-filings/bicycle-therapeutics-shareholders-approve-all-proposals-at-annual-general-meeting-93CH-4335236", "source_name": "Investing.com South Africa", "published_at": "2026-06-18T13:43:44", "published_display": "18 Jun 2026 13:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics (BCYC) AGM approves directors, PwC and pay", "summary": "Bicycle Therapeutics plc (BCYC) shareholders approved all nine proposals at its Annual General Meeting (AGM) held on June 17, 2026. Key approvals included the re-election of directors Felix Baker and Herv\u00e9 Hoppenot, advisory approval of executive compensation, and the ratificatio", "url": "https://www.stocktitan.net/sec-filings/BCYC/8-k-bicycle-therapeutics-plc-reports-material-event-dcac526ac0a0.html", "source_name": "Stock Titan", "published_at": "2026-06-18T12:10:44", "published_display": "18 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics PLC (BCYC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a title for \"Bicycle Therapeutics PLC (BCYC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution\" but states that relevant data concerning the company's revenue breakdown by business segment and region has not yet been disclosed. It a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcyc/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T03:10:44", "published_display": "18 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics PLC (BCYC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Bicycle Therapeutics PLC (BCYC) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have set an average price target of $16.00, with a high of $44.00 and a low of $6.00, primarily recommending a \"Buy.\" The company's ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcyc/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T12:10:27", "published_display": "17 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics: Trading Below Cash Amid Multiple Uncertainties (NASDAQ:BCYC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPZVNfMjJfS05uUDkzMlJJbF9Xa3A1UUJSTUp1Vzk1LU5SbTg0a1BXampuR1pFdzRGbXh3LW43N3hrMFpiVDg1bFhIbExUMUhNc1IwZnNQYm5IQVJ1UjJ2TVZUeUZSM3lXcDBibU5uTE1hT3ZvYWs1c0F5WFpRQjNaRVhTX1RCOHhMa1NOOG05YzhQVnhVODkxeWg0cGlRSzVMNnBOam9scllIenFF?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting", "summary": "Bicycle Therapeutics will present initial data from its randomized Phase 2 Duravelo-2 trial and updated Phase 1 Duravelo-1 trial data at the 2026 ASCO Annual Meeting. The data shows that zelenectide pevedotin (zelenectide) in combination with pembrolizumab achieved encouraging re", "url": "https://www.pharmiweb.com/press-release/2026-05-22-4/bicycle-therapeutics-to-present-initial-duravelo-2-data-at-2026-asco-annual-meeting", "source_name": "PharmiWeb.com", "published_at": "2026-05-21T23:39:41", "published_display": "21 May 2026 23:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics presents initial Duravelo-2 data showing comparable ORR and lower toxicity in mUC", "summary": "Bicycle Therapeutics announced initial Duravelo-2 data for zelenectide in metastatic urothelial cancer, showing comparable response rates and a potentially differentiated safety profile. Data from Duravelo-2 and updated Duravelo-1 trials highlighted high objective response rates ", "url": "https://www.tradingview.com/news/tradingview:cf3f41dc28458:0-bicycle-therapeutics-presents-initial-duravelo-2-data-showing-comparable-orr-and-lower-toxicity-in-muc/", "source_name": "TradingView", "published_at": "2026-05-21T21:39:05", "published_display": "21 May 2026 21:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bladder cancer drug shows 4x fewer skin side effects than standard care", "summary": "Bicycle Therapeutics announced initial data from its Phase 2 (Duravelo-2) trial and updated data from its Phase 1 (Duravelo-1) trial for zelenectide pevedotin in metastatic urothelial cancer (mUC). The drug, in combination with pembrolizumab, showed comparable response rates to s", "url": "https://www.stocktitan.net/news/BCYC/bicycle-therapeutics-to-present-initial-duravelo-2-data-at-2026-asco-3yqu06e6alx3.html", "source_name": "Stock Titan", "published_at": "2026-05-21T20:39:05", "published_display": "21 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Duravelo-2 bladder cancer data from Bicycle (NASDAQ: BCYC)", "summary": "Bicycle Therapeutics (NASDAQ: BCYC) has released initial Duravelo-2 and updated Duravelo-1 clinical data for zelenectide pevedotin in metastatic urothelial cancer. The data indicate response rates and progression-free survival comparable to standard-of-care, alongside a potential", "url": "https://www.stocktitan.net/sec-filings/BCYC/8-k-bicycle-therapeutics-plc-reports-material-event-4db8c6ea7072.html", "source_name": "Stock Titan", "published_at": "2026-05-21T20:39:05", "published_display": "21 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Armistice Capital/Steven Boyd disclose 6.75% stake in Bicycle Therapeutics (BCYC)", "summary": "Armistice Capital, LLC and Steven Boyd have disclosed a 6.75% beneficial ownership stake in Bicycle Therapeutics (BCYC), totaling 3,398,000 American Depositary Shares (ADS) via a SCHEDULE 13G/A SEC filing. Armistice Capital, as the investment manager for a Master Fund, exercises ", "url": "https://www.stocktitan.net/sec-filings/BCYC/schedule-13g-a-bicycle-therapeutics-plc-amended-passive-investment-di-f8954d98fb50.html", "source_name": "Stock Titan", "published_at": "2026-05-15T15:08:51", "published_display": "15 May 2026 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Long Focus Capital (NASDAQ: BCYC) holds 3,310,687 ADS (6.6%)", "summary": "Long Focus Capital Management, LLC and John Helmers have disclosed beneficial ownership of 3,310,687 American Depositary Shares (ADS) of Bicycle Therapeutics plc (NASDAQ: BCYC), representing 6.6% of the class. This passive investment, reported via a Schedule 13G filing, indicates", "url": "https://www.stocktitan.net/sec-filings/BCYC/schedule-13g-bicycle-therapeutics-plc-passive-investment-disclosure-5-a8188cf8d4ea.html", "source_name": "Stock Titan", "published_at": "2026-05-15T13:08:52", "published_display": "15 May 2026 13:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "After plunging 20.2% in 4 weeks, here's why the trend might reverse for Bicycle Therapeutics (BCYC)", "summary": "This article discusses the recent 20.2% decline in Bicycle Therapeutics (BCYC) stock over the past four weeks and explores potential reasons why this downward trend could reverse. It suggests that despite the recent plunge, there might be underlying factors or upcoming events tha", "url": "https://www.msn.com/en-us/technology/general/after-plunging-20-2-in-4-weeks-here-s-why-the-trend-might-reverse-for-bicycle-therapeutics-bcyc/ar-AA1ZiZ9i?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-15T05:40:14", "published_display": "15 May 2026 05:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Five ASCO studies put Bicycle Therapeutics' cancer drug in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPM2JBTldFaU1TdlZMWTI4U1NyWVdOWEdWVGdmZERkNy11ckl1bC02OGV4cmpIdFdab3ZpRGJaQnh1SWN6N0dJRnZBd0NYcWxXOEtXT1lNaXI1Z3ZadkU5SThSUXhYRWgzN0N5WkVHN0FsWWNfNnloamp5Ym5OM0JndGZNTHd4V3M5OUI2RW40RUV1c2VXTk1tZTMwM3hsZjJvYXRlOUhUd1hhWjVWdXFicjZ3VUR6WWo0S0x4c0c4Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bicycle Therapeutics doses first patient in pancreatic cancer trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNbTNZRmtfcUZBR2hkVEVMcHdrQzN3cm9vbFgtNktZXzJuQzZDZUtWajFwa0ZKV3VEZDZ0eDR6bzFfZ1hsLTVBUHRWWUl6aFBBdXQ2RlMwNmZIcmdaRWJUQllVMG51ZG5MaklEMVlkbElJdmRTX1dJcWFsUHVnSUU2OUJvamtCUDZjYlFGUkJPSkU5U2xoVVpTWm9yci14TlJtUTlBQjl6eHVsMVdYanJGeVE2VVVONzdXd1ZMdTBnd0kwdw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Updates Bicycle Therapeutics plc (BCYC) Outlook Amid Pipeline Refocus", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOOTR5ai1jZV9zaTQxWF9FRnc0RVp4aUtZNmJsVlk5cU9yVTJfVkRFaEZGcExfVi0tZEJidWJGYVlEM3J2Z1ZjZWRsZU5KeVc5QV8ycFVXblotTXNnb0ZiYTYtMEZwNTFYaGVlU3QyMjZiSTlQSWk3ek9neEtmZG8zVkhaUW5GSUdYSFIyb09UeElQTnpBNUUzcEg4eVlWUjlkaTBFUmljMG5RRXNJR2pvQm9n?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPVlBVZXA5S1lZYlJESVJsY2hGWkdhWTd4clRNY1ZDOEdsQUFJNDhqd2pkODh0cElHNFhQZ3FxeTRWMlE5RzJ6Yks4R0x4SkhSV0RuQ2FIMGEzd0puU1A2bUtHelpMYmQ5OTAxSUhhXzJ1MTNRMmpMS0hweXd1ekw0WVduM2ZfdDJReXhlQjRPMEYxWHJmX1d3eWZFZnlycTJIdkN3?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Lowers its Price Target on Bicycle Therapeutics plc (BCYC) to $7 from $11", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPRzdZLVN5YjdpTEl3SDNMeVJ6dF8wVXpKQ0FUdEJiVm9aNFI1Ui1VdkI5X2oxSmhBbFpPVFZybzRwZnJ3Ui1qSTRMRHAtdWhjRGlaYURobWpNVmxlS1JsXzZoNVVUVlN5NUEyS1FHM1VnWV9kLUdNSk92RS15QXpGR3h2SjM3VHRObE9nclVSbFZyb1dFTGtoVDcteko3SG94b1E?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOUjVPdzVGeU9EaWxFbW0xTEhITjVQSzQ0dkFSWGtBb0NTSmt0VmF5ZWxlQlhfYkI1NXh6OFdMakM2ZVB6MnkySzNyQ2FyS3dXckIyTHNPemtSQlBoNS11b3NycHVRYW1jTzFSemppbUtCRkFHaG1lTEQ3Mk9VM283TWlXeG9UZG5SMzdLa05BaWlGWDBNYmV4VkdoaldkMlNT?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics (BCYC) Quarterly Loss Of US$59.1 Million Tests Growth Focus Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics changes priorities, announces layoffs", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNUmljMzNmOFMxZXd2QjVLLVkwNTJuY0FIak5VVHFvWjlpd05WY2JQS2g5TzFnSkIwRU13b0FOa09HdE9mUTVZLVlhZnlQMm1TR0IydkpHYzdSR0k4UkVEYXRUZW92REZ1Q2ZIQmNJdlZwOHVCWDNucVFpYmNPVDZiS2FRU21nT2Z0VnV2aHVLOS1fa0x6dzlhdTJrcw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics (BCYC) Appoints Travis Thompson as CFO Following Leadership Transitions", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQenZCZXZDcmFjR05xRy00bk1jWFNkU0xHWFVXTXpCZXU4UGt4VUVrb1Z2eHVOaE00d3QtWmJ5NDJWS2dXc3F6aGdjajdkNTE5VzFnSkllLWsyQW9vSWZuc3YzdzVUMFpENjBxeE1Na2lFV2lRWWkyMl8zRkZGaS0zVkh1U0J1RTBrVlM0TXpzMVE?oc=5", "source_name": "Market source", "published_at": "2026-03-14T07:00:00+00:00", "published_display": "14 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Bicycle Therapeutics (NASDAQ:BCYC) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Don't Ignore The Insider Selling In Bicycle Therapeutics", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics plc (NASDAQ:BCYC) has caught the attention of institutional investors who hold a sizeable 45% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPZmdtRGdIemN3TkNtS19xRjZTZllnX2NqSkNCOGZjanhWZVhELWlXNU9MMFN1VzNYX2haS1Zubk44cWJlemx6Z0hnY25leEd0eGtGWnEtMUNPaElpcW5iZzg1cVdKRlluYzZBUVdXelRfSlk1cDJwWGJvbnh0b1Vndk5UcnRIZ3M5OGc?oc=5", "source_name": "Market source", "published_at": "2025-09-12T07:00:00+00:00", "published_display": "12 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Just Slashed Their Bicycle Therapeutics plc (NASDAQ:BCYC) EPS Numbers", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-18T07:00:00+00:00", "published_display": "18 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOd3d1Q2lnZzhnY05Fa1VGSHNIem5uc21NT29Oal9LV0trY0lReG9lQVNqd1lwVkRVVE9KWHRfNHhfQ3RNOTZscHNFTy02X05EeE5RYnZ1NDRxWXhBaUJqZWx2a3lxTnV3Nl9tZ1VMVEt6a2I5djgtaUlRVmxWbWdITVBNdUd4eEJObVp5RldCN1ZMOVBtbG5QVTlEVkNseFgtd0NfdW4xb2p0eUVhbHhwelJpcndOcWc?oc=5", "source_name": "citybiz", "published_at": "2024-05-23T07:00:00+00:00", "published_display": "23 May 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPS2dKVlNjbnVSdklTRVQtQnVSaU4yQ2RKOXY5bkF0NDFQNllJZTZhSG84YTJFRW5NeElTUy1CSjdZekpvdmdxTWp6eGdFc281YTNPV0FlZG9jaDJ3cGwycXdqVVJOaEQ4RUJqZGhua3gySl9zaXJkR0xXMGlHVTMxZ1Q1YV9FeGdyM2tUVktqTVFkX1k0MURDZDIyNnd2NDI4Y2tENERhbTRzYThZeTNVQWxpV3JES2haLUkwWDQyMkNrbDlFeElvaHZLVmo4UWlWdUF4LTJJa2hUcVZ6YjRiaEJzNWptWExkcEJ1MlJ0WlZvRm9iWndr?oc=5", "source_name": "Bayer", "published_at": "2023-05-10T07:00:00+00:00", "published_display": "10 May 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ETFs Investing in Bicycle Therapeutics Plc Sponsored ADR Stocks", "summary": "This article lists various ETFs that hold shares of Bicycle Therapeutics Plc Sponsored ADR, providing details such as market value, weight, issuer, expense ratio, and recent performance. The funds are primarily focused on the healthcare and biotechnology sectors, offering investo", "url": "https://www.tradingview.com/symbols/SWB-50BA/etfs/", "source_name": "TradingView", "published_at": "2026-07-14T04:42:40", "published_display": "14 Jul 2026 04:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics (BCYC) CSO executes small RSU tax sell-to-cover trades", "summary": "Bicycle Therapeutics' Chief Scientific Officer, Michael Skynner, conducted two small \"sell-to-cover\" transactions to meet tax withholding obligations on vested Restricted Stock Units (RSUs). These sales, occurring on July 2 and July 6, 2026, involved a total of 2,391 Ordinary Sha", "url": "https://www.stocktitan.net/sec-filings/BCYC/form-4-bicycle-therapeutics-plc-insider-trading-activity-df7ecf8530d6.html", "source_name": "Stock Titan", "published_at": "2026-07-08T12:09:52", "published_display": "08 Jul 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BICYCLE THERAPEUTICS (BCYC) CEO executes 7,642-share tax sell-to-cover", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOZnJCbGNDV0NpT2txem4wRUpvYXJyMktrNjZKZy1fdVBVTzZwZFVpZjJ2SWRHMktPbW5QQW9PT0pEZFZaaDdaMDdXS050TTFod3B0U3IzSmxTUDNjMWU3c3phemM3ZkNUbTQxdDRncldMa0hkeUQyRnpNWmdEaWdLUUw1WlRrQ0lsXzdKcnNRTnBkVXItQnJxNGRCNXFtMWh1b1lIeFpTc2l5MEJrMmJZWFlQT0xidDl0OEE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T21:00:57+00:00", "published_display": "07 Jul 2026 21:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics (BCYC) executive sells shares to cover RSU tax withholding", "summary": "Bicycle Therapeutics (BCYC) executive Michael Charles Ferguson sold 1,761 Ordinary Shares across two transactions at weighted average prices of approximately $4.27 and $4.31. These sales were not discretionary but mandated \"sell to cover\" transactions to satisfy statutory tax wit", "url": "https://www.stocktitan.net/sec-filings/BCYC/form-4-bicycle-therapeutics-plc-insider-trading-activity-7ca9bc4981cb.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:35", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics (BCYC) COO sells 1,412 shares in tax-related trades", "summary": "Bicycle Therapeutics COO Jennifer Scott Perry sold 1,412 Ordinary Shares in tax-related transactions on July 2 and July 6, 2026, at prices between $4.27 and $4.34 per share. These sales were mandated \"sell to cover\" for statutory tax withholding obligations from RSU vesting, not ", "url": "https://www.stocktitan.net/sec-filings/BCYC/form-4-bicycle-therapeutics-plc-insider-trading-activity-0479129bb7fd.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:35", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics (BCYC) CFO files sell-to-cover sale of 923 shares", "summary": "Bicycle Therapeutics CFO Travis Alvin Thompson reported a \"sell-to-cover\" sale of 923 Ordinary Shares in two open-market transactions. These sales, totaling $3,945, were executed at weighted average prices of $4.27 and $4.31 to fulfill statutory tax withholding obligations on ves", "url": "https://www.stocktitan.net/sec-filings/BCYC/form-4-bicycle-therapeutics-plc-insider-trading-activity-c34f9f68fd89.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:40:35", "published_display": "07 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Bicycle Therapeutics Limited (BCYC)", "summary": "This article analyzes the historical performance of investing $1,000 in Bicycle Therapeutics Limited (BCYC) over various periods, showing significant declines over one and five years. It details the company's focus on developing Bicycle\u00ae molecules for oncology, including drug con", "url": "https://www.stocktitan.net/tools/stock-return-calculator/BCYC", "source_name": "Stock Titan", "published_at": "2026-07-04T23:11:16", "published_display": "04 Jul 2026 23:11", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BCYC (Nasdaq: BCYC) files Rule 144 notice listing RSUs and prior sale", "summary": "Bicycle Therapeutics PLC (BCYC) has filed a Rule 144 notice detailing the proposed sale of common stock and restricted stock units. The filing specifies 12,513 restricted stock units dated July 2, 2026, and 3,594 restricted stock units dated July 3, 2026, alongside a prior sale o", "url": "https://www.stocktitan.net/sec-filings/BCYC/144-bicycle-therapeutics-plc-sec-filing-ff2ed0b717b9.html", "source_name": "Stock Titan", "published_at": "2026-07-02T19:40:02", "published_display": "02 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Bicycle Therapeutics plc \u2013 NASDAQ:BCYC", "summary": "This article focuses on the \"Price to sales forward\" financial metric for Bicycle Therapeutics plc (NASDAQ: BCYC). It appears to be a stub or a data point from a larger financial analysis platform, providing a snapshot of this specific valuation ratio without further narrative. T", "url": "https://www.tradingview.com/symbols/NASDAQ-BCYC/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:39:49", "published_display": "27 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Bicycle Therapeutics plc \u2013 NASDAQ:BCYC", "summary": "The article focuses on the \"Price to earnings forward\" metric for Bicycle Therapeutics plc (NASDAQ: BCYC). It indicates that the market was closed at the time of publication with no trades having occurred. The page provides general financial information and market data for the co", "url": "https://www.tradingview.com/symbols/NASDAQ-BCYC/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:41:12", "published_display": "27 Jun 2026 19:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Bicycle Therapeutics Plc Sponsored ADR \u2013 FWB:50BA", "summary": "This article displays the \"Price to earnings forward\" value for Bicycle Therapeutics Plc Sponsored ADR (FWB:50BA) on the Frankfurt Stock Exchange. It provides a financial overview of the company, indicating the market was closed with no trades at the time of viewing. The content ", "url": "https://www.tradingview.com/symbols/FWB-50BA/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T18:40:26", "published_display": "27 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Bicycle Therapeutics plc \u2013 NASDAQ:BCYC", "summary": "This article provides financial information for Bicycle Therapeutics plc (NASDAQ:BCYC), specifically focusing on its \"Price to book forward\" metric. The content indicates that the market for BCYC was closed at the time of publication, with no trades occurring. The article is part", "url": "https://www.tradingview.com/symbols/NASDAQ-BCYC/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T13:40:26", "published_display": "27 Jun 2026 13:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics Plc Sponsored ADR Actuals & Estimates (NASDAQ:BCYC)", "summary": "This page provides an overview of Bicycle Therapeutics Plc (NASDAQ:BCYC) financial actuals and analyst estimates. Users can explore reported financial data across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average", "url": "https://www.tradingview.com/symbols/NASDAQ-BCYC/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-27T12:39:23", "published_display": "27 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Bicycle Therapeutics Plc Sponsored ADR \u2013 FWB:50BA", "summary": "This article provides financial data for Bicycle Therapeutics Plc Sponsored ADR (FWB:50BA), specifically focusing on its price-to-sales forward ratio. It highlights the company's financial overview on the Frankfurt Stock Exchange via TradingView, indicating that the market was cl", "url": "https://www.tradingview.com/symbols/FWB-50BA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:41:12", "published_display": "27 Jun 2026 07:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "50BA Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides the forecast and price target for Bicycle Therapeutics Plc (50BA) trading on the Frankfurt Stock Exchange. It notes a price target of 11.08 based on 9 analysts' 1-year forecasts and mentions that 11 analysts have given stock ratings in the past three months.", "url": "https://www.tradingview.com/symbols/FWB-50BA/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T08:40:40", "published_display": "26 Jun 2026 08:40", "sentiment": "positive", "sentiment_pct": 63, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics PLC (BCYC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Bicycle Therapeutics PLC (BCYC), noting its current valuation score of 7.85 within the Biotechnology & Medical Research industry. It highlights that the company's P/E ratio is -1.25, while data for P/B, P/S, and P/CF ratios are not ye", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcyc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-25T10:11:44", "published_display": "25 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics shareholders approve all proposals at annual general meeting", "summary": "Bicycle Therapeutics plc announced that all proposals presented at its annual general meeting of shareholders were approved. Shareholders re-elected Felix Baker and Herv\u00e9 Hoppenot as directors, approved executive officer compensation, and ratified the appointments of Pricewaterho", "url": "https://ng.investing.com/news/sec-filings/bicycle-therapeutics-shareholders-approve-all-proposals-at-annual-general-meeting-93CH-2565300", "source_name": "Investing.com Nigeria", "published_at": "2026-06-18T16:10:25", "published_display": "18 Jun 2026 16:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics shareholders approve all proposals at annual general meeting By Investing.com", "summary": "Bicycle Therapeutics plc announced that all proposals at its annual general meeting were approved by shareholders. Resolutions included the re-election of Felix Baker and Herv\u00e9 Hoppenot as directors, advisory approval of executive compensation, and the ratification and re-appoint", "url": "https://za.investing.com/news/sec-filings/bicycle-therapeutics-shareholders-approve-all-proposals-at-annual-general-meeting-93CH-4335236", "source_name": "Investing.com South Africa", "published_at": "2026-06-18T13:43:44", "published_display": "18 Jun 2026 13:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics (BCYC) AGM approves directors, PwC and pay", "summary": "Bicycle Therapeutics plc (BCYC) shareholders approved all nine proposals at its Annual General Meeting (AGM) held on June 17, 2026. Key approvals included the re-election of directors Felix Baker and Herv\u00e9 Hoppenot, advisory approval of executive compensation, and the ratificatio", "url": "https://www.stocktitan.net/sec-filings/BCYC/8-k-bicycle-therapeutics-plc-reports-material-event-dcac526ac0a0.html", "source_name": "Stock Titan", "published_at": "2026-06-18T12:10:44", "published_display": "18 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics PLC (BCYC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article provides a title for \"Bicycle Therapeutics PLC (BCYC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution\" but states that relevant data concerning the company's revenue breakdown by business segment and region has not yet been disclosed. It a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcyc/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T03:10:44", "published_display": "18 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics PLC (BCYC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Bicycle Therapeutics PLC (BCYC) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have set an average price target of $16.00, with a high of $44.00 and a low of $6.00, primarily recommending a \"Buy.\" The company's ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-bcyc/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T12:10:27", "published_display": "17 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics: Trading Below Cash Amid Multiple Uncertainties (NASDAQ:BCYC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPZVNfMjJfS05uUDkzMlJJbF9Xa3A1UUJSTUp1Vzk1LU5SbTg0a1BXampuR1pFdzRGbXh3LW43N3hrMFpiVDg1bFhIbExUMUhNc1IwZnNQYm5IQVJ1UjJ2TVZUeUZSM3lXcDBibU5uTE1hT3ZvYWs1c0F5WFpRQjNaRVhTX1RCOHhMa1NOOG05YzhQVnhVODkxeWg0cGlRSzVMNnBOam9scllIenFF?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting", "summary": "Bicycle Therapeutics will present initial data from its randomized Phase 2 Duravelo-2 trial and updated Phase 1 Duravelo-1 trial data at the 2026 ASCO Annual Meeting. The data shows that zelenectide pevedotin (zelenectide) in combination with pembrolizumab achieved encouraging re", "url": "https://www.pharmiweb.com/press-release/2026-05-22-4/bicycle-therapeutics-to-present-initial-duravelo-2-data-at-2026-asco-annual-meeting", "source_name": "PharmiWeb.com", "published_at": "2026-05-21T23:39:41", "published_display": "21 May 2026 23:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics presents initial Duravelo-2 data showing comparable ORR and lower toxicity in mUC", "summary": "Bicycle Therapeutics announced initial Duravelo-2 data for zelenectide in metastatic urothelial cancer, showing comparable response rates and a potentially differentiated safety profile. Data from Duravelo-2 and updated Duravelo-1 trials highlighted high objective response rates ", "url": "https://www.tradingview.com/news/tradingview:cf3f41dc28458:0-bicycle-therapeutics-presents-initial-duravelo-2-data-showing-comparable-orr-and-lower-toxicity-in-muc/", "source_name": "TradingView", "published_at": "2026-05-21T21:39:05", "published_display": "21 May 2026 21:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bladder cancer drug shows 4x fewer skin side effects than standard care", "summary": "Bicycle Therapeutics announced initial data from its Phase 2 (Duravelo-2) trial and updated data from its Phase 1 (Duravelo-1) trial for zelenectide pevedotin in metastatic urothelial cancer (mUC). The drug, in combination with pembrolizumab, showed comparable response rates to s", "url": "https://www.stocktitan.net/news/BCYC/bicycle-therapeutics-to-present-initial-duravelo-2-data-at-2026-asco-3yqu06e6alx3.html", "source_name": "Stock Titan", "published_at": "2026-05-21T20:39:05", "published_display": "21 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Duravelo-2 bladder cancer data from Bicycle (NASDAQ: BCYC)", "summary": "Bicycle Therapeutics (NASDAQ: BCYC) has released initial Duravelo-2 and updated Duravelo-1 clinical data for zelenectide pevedotin in metastatic urothelial cancer. The data indicate response rates and progression-free survival comparable to standard-of-care, alongside a potential", "url": "https://www.stocktitan.net/sec-filings/BCYC/8-k-bicycle-therapeutics-plc-reports-material-event-4db8c6ea7072.html", "source_name": "Stock Titan", "published_at": "2026-05-21T20:39:05", "published_display": "21 May 2026 20:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Armistice Capital/Steven Boyd disclose 6.75% stake in Bicycle Therapeutics (BCYC)", "summary": "Armistice Capital, LLC and Steven Boyd have disclosed a 6.75% beneficial ownership stake in Bicycle Therapeutics (BCYC), totaling 3,398,000 American Depositary Shares (ADS) via a SCHEDULE 13G/A SEC filing. Armistice Capital, as the investment manager for a Master Fund, exercises ", "url": "https://www.stocktitan.net/sec-filings/BCYC/schedule-13g-a-bicycle-therapeutics-plc-amended-passive-investment-di-f8954d98fb50.html", "source_name": "Stock Titan", "published_at": "2026-05-15T15:08:51", "published_display": "15 May 2026 15:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Long Focus Capital (NASDAQ: BCYC) holds 3,310,687 ADS (6.6%)", "summary": "Long Focus Capital Management, LLC and John Helmers have disclosed beneficial ownership of 3,310,687 American Depositary Shares (ADS) of Bicycle Therapeutics plc (NASDAQ: BCYC), representing 6.6% of the class. This passive investment, reported via a Schedule 13G filing, indicates", "url": "https://www.stocktitan.net/sec-filings/BCYC/schedule-13g-bicycle-therapeutics-plc-passive-investment-disclosure-5-a8188cf8d4ea.html", "source_name": "Stock Titan", "published_at": "2026-05-15T13:08:52", "published_display": "15 May 2026 13:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After plunging 20.2% in 4 weeks, here's why the trend might reverse for Bicycle Therapeutics (BCYC)", "summary": "This article discusses the recent 20.2% decline in Bicycle Therapeutics (BCYC) stock over the past four weeks and explores potential reasons why this downward trend could reverse. It suggests that despite the recent plunge, there might be underlying factors or upcoming events tha", "url": "https://www.msn.com/en-us/technology/general/after-plunging-20-2-in-4-weeks-here-s-why-the-trend-might-reverse-for-bicycle-therapeutics-bcyc/ar-AA1ZiZ9i?ocid=BingNewsVerp&apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-15T05:40:14", "published_display": "15 May 2026 05:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Five ASCO studies put Bicycle Therapeutics' cancer drug in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPM2JBTldFaU1TdlZMWTI4U1NyWVdOWEdWVGdmZERkNy11ckl1bC02OGV4cmpIdFdab3ZpRGJaQnh1SWN6N0dJRnZBd0NYcWxXOEtXT1lNaXI1Z3ZadkU5SThSUXhYRWgzN0N5WkVHN0FsWWNfNnloamp5Ym5OM0JndGZNTHd4V3M5OUI2RW40RUV1c2VXTk1tZTMwM3hsZjJvYXRlOUhUd1hhWjVWdXFicjZ3VUR6WWo0S0x4c0c4Zw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics doses first patient in pancreatic cancer trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNbTNZRmtfcUZBR2hkVEVMcHdrQzN3cm9vbFgtNktZXzJuQzZDZUtWajFwa0ZKV3VEZDZ0eDR6bzFfZ1hsLTVBUHRWWUl6aFBBdXQ2RlMwNmZIcmdaRWJUQllVMG51ZG5MaklEMVlkbElJdmRTX1dJcWFsUHVnSUU2OUJvamtCUDZjYlFGUkJPSkU5U2xoVVpTWm9yci14TlJtUTlBQjl6eHVsMVdYanJGeVE2VVVONzdXd1ZMdTBnd0kwdw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Updates Bicycle Therapeutics plc (BCYC) Outlook Amid Pipeline Refocus", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOOTR5ai1jZV9zaTQxWF9FRnc0RVp4aUtZNmJsVlk5cU9yVTJfVkRFaEZGcExfVi0tZEJidWJGYVlEM3J2Z1ZjZWRsZU5KeVc5QV8ycFVXblotTXNnb0ZiYTYtMEZwNTFYaGVlU3QyMjZiSTlQSWk3ek9neEtmZG8zVkhaUW5GSUdYSFIyb09UeElQTnpBNUUzcEg4eVlWUjlkaTBFUmljMG5RRXNJR2pvQm9n?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPVlBVZXA5S1lZYlJESVJsY2hGWkdhWTd4clRNY1ZDOEdsQUFJNDhqd2pkODh0cElHNFhQZ3FxeTRWMlE5RzJ6Yks4R0x4SkhSV0RuQ2FIMGEzd0puU1A2bUtHelpMYmQ5OTAxSUhhXzJ1MTNRMmpMS0hweXd1ekw0WVduM2ZfdDJReXhlQjRPMEYxWHJmX1d3eWZFZnlycTJIdkN3?oc=5", "source_name": "Market source", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RBC Capital Lowers its Price Target on Bicycle Therapeutics plc (BCYC) to $7 from $11", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPRzdZLVN5YjdpTEl3SDNMeVJ6dF8wVXpKQ0FUdEJiVm9aNFI1Ui1VdkI5X2oxSmhBbFpPVFZybzRwZnJ3Ui1qSTRMRHAtdWhjRGlaYURobWpNVmxlS1JsXzZoNVVUVlN5NUEyS1FHM1VnWV9kLUdNSk92RS15QXpGR3h2SjM3VHRObE9nclVSbFZyb1dFTGtoVDcteko3SG94b1E?oc=5", "source_name": "Market source", "published_at": "2026-04-04T07:00:00+00:00", "published_display": "04 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOUjVPdzVGeU9EaWxFbW0xTEhITjVQSzQ0dkFSWGtBb0NTSmt0VmF5ZWxlQlhfYkI1NXh6OFdMakM2ZVB6MnkySzNyQ2FyS3dXckIyTHNPemtSQlBoNS11b3NycHVRYW1jTzFSemppbUtCRkFHaG1lTEQ3Mk9VM283TWlXeG9UZG5SMzdLa05BaWlGWDBNYmV4VkdoaldkMlNT?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics (BCYC) Quarterly Loss Of US$59.1 Million Tests Growth Focus Narrative", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics changes priorities, announces layoffs", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNUmljMzNmOFMxZXd2QjVLLVkwNTJuY0FIak5VVHFvWjlpd05WY2JQS2g5TzFnSkIwRU13b0FOa09HdE9mUTVZLVlhZnlQMm1TR0IydkpHYzdSR0k4UkVEYXRUZW92REZ1Q2ZIQmNJdlZwOHVCWDNucVFpYmNPVDZiS2FRU21nT2Z0VnV2aHVLOS1fa0x6dzlhdTJrcw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics (BCYC) Appoints Travis Thompson as CFO Following Leadership Transitions", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxQenZCZXZDcmFjR05xRy00bk1jWFNkU0xHWFVXTXpCZXU4UGt4VUVrb1Z2eHVOaE00d3QtWmJ5NDJWS2dXc3F6aGdjajdkNTE5VzFnSkllLWsyQW9vSWZuc3YzdzVUMFpENjBxeE1Na2lFV2lRWWkyMl8zRkZGaS0zVkh1U0J1RTBrVlM0TXpzMVE?oc=5", "source_name": "Market source", "published_at": "2026-03-14T07:00:00+00:00", "published_display": "14 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Bicycle Therapeutics (NASDAQ:BCYC) Needs To Drive Business Growth Carefully", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Don't Ignore The Insider Selling In Bicycle Therapeutics", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-10T08:00:00+00:00", "published_display": "10 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics plc (NASDAQ:BCYC) has caught the attention of institutional investors who hold a sizeable 45% stake", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPZmdtRGdIemN3TkNtS19xRjZTZllnX2NqSkNCOGZjanhWZVhELWlXNU9MMFN1VzNYX2haS1Zubk44cWJlemx6Z0hnY25leEd0eGtGWnEtMUNPaElpcW5iZzg1cVdKRlluYzZBUVdXelRfSlk1cDJwWGJvbnh0b1Vndk5UcnRIZ3M5OGc?oc=5", "source_name": "Market source", "published_at": "2025-09-12T07:00:00+00:00", "published_display": "12 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Just Slashed Their Bicycle Therapeutics plc (NASDAQ:BCYC) EPS Numbers", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-18T07:00:00+00:00", "published_display": "18 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bicycle Therapeutics Announces $555 Million Private Placement Equity Financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOd3d1Q2lnZzhnY05Fa1VGSHNIem5uc21NT29Oal9LV0trY0lReG9lQVNqd1lwVkRVVE9KWHRfNHhfQ3RNOTZscHNFTy02X05EeE5RYnZ1NDRxWXhBaUJqZWx2a3lxTnV3Nl9tZ1VMVEt6a2I5djgtaUlRVmxWbWdITVBNdUd4eEJObVp5RldCN1ZMOVBtbG5QVTlEVkNseFgtd0NfdW4xb2p0eUVhbHhwelJpcndOcWc?oc=5", "source_name": "citybiz", "published_at": "2024-05-23T07:00:00+00:00", "published_display": "23 May 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9wFBVV95cUxPS2dKVlNjbnVSdklTRVQtQnVSaU4yQ2RKOXY5bkF0NDFQNllJZTZhSG84YTJFRW5NeElTUy1CSjdZekpvdmdxTWp6eGdFc281YTNPV0FlZG9jaDJ3cGwycXdqVVJOaEQ4RUJqZGhua3gySl9zaXJkR0xXMGlHVTMxZ1Q1YV9FeGdyM2tUVktqTVFkX1k0MURDZDIyNnd2NDI4Y2tENERhbTRzYThZeTNVQWxpV3JES2haLUkwWDQyMkNrbDlFeElvaHZLVmo4UWlWdUF4LTJJa2hUcVZ6YjRiaEJzNWptWExkcEJ1MlJ0WlZvRm9iWndr?oc=5", "source_name": "Bayer", "published_at": "2023-05-10T07:00:00+00:00", "published_display": "10 May 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 95, "total_relevant": 52, "sentiment_summary": {"positive": 11, "negative": 2, "neutral": 39, "score": 54, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 15.2, "count": 27}, {"event": "earnings", "label": "Earnings", "weight": 6.6, "count": 14}, {"event": "macro", "label": "Macro sensitivity", "weight": 1.65, "count": 3}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}], "positive_events": 11, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 4.41, "latest_week": "2026-07-10", "one_week_move": 1.4, "four_week_move": 8.9, "twelve_week_move": -17.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.302701, "market_dynamics_buy_signal": false, "relative_strength": -39.72142, "fair_value_gap": -68.7, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 38.6142, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.4% over one week, +8.9% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 13}, {"label": "Market source", "count": 11}, {"label": "TradingView", "count": 10}, {"label": "simplywall.st", "count": 6}, {"label": "TradingKey", "count": 3}, {"label": "Seeking Alpha", "count": 2}, {"label": "Investing.com Nigeria", "count": 1}, {"label": "Investing.com South Africa", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 44}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 27}, {"label": "Earnings", "count": 14}, {"label": "Macro sensitivity", "count": 3}, {"label": "Guidance", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Deals and strategy", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "44", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.4% over one week, +8.9% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ETFs Investing in Bicycle Therapeutics Plc Sponsored ADR Stocks"}], "updated_at": "2026-07-16T00:47:44.734258+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}